Trials / Terminated
TerminatedNCT04678453
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Alzheimer's Disease (AD)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- NKGen Biotech, Inc. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent, for the treatment of subjects with Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SNK01 | Patient-specific ex vivo expanded autologous natural killer cells |
Timeline
- Start date
- 2021-01-06
- Primary completion
- 2023-08-16
- Completion
- 2024-01-31
- First posted
- 2020-12-22
- Last updated
- 2024-03-01
Locations
1 site across 1 country: Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04678453. Inclusion in this directory is not an endorsement.